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OBJECTIVES: To assess the cost-effectiveness of three treat-
ments (tiotropium, salmeterol, and no treatment) in patients with
moderate chronic obstructive pulmonary disease (COPD).
METHODS: A Markov model with a time horizon of one year
was developed to evaluate the cost-effectiveness of three treat-
ments including i) tiotropium, ii) salmeterol, and iii) no treat-
ment, in patients with moderate COPD. A hypothetical cohort
of 100,000 subjects with moderate COPD with the following
characteristics were included in the model: mean age of 65 years,
smoking history of 50 pack years, and disease duration of 9.5
years. The efﬁcacy and withdrawal data was taken from pub-
lished randomized clinical trials of the treatments conducted in
patients with moderate COPD. The effectiveness measure was
exacerbations avoided per patient per year. Incremental cost-
effectiveness ratio (ICER) was calculated as additional cost per
patient to prevent one exacerbation, compared with the next
most expensive option. A payer’s perspective was used and only
direct costs were included in the study. Sensitivity analyses were
conducted to test the robustness of the baseline estimates and the
study assumptions. RESULTS: The mean annual costs for 
no treatment, salmeterol, and tiotropium groups were $392,
$1268.7 and $1408.6, respectively. The ICER of tiotropium
compared with no treatment group was $1830.46/exacerbation
avoided, while the ICER of salmeterol compared with no treat-
ment group was $2454.35/exacerbation avoided. Sensitivity
analysis results for study variables were stable over a wide range;
however the results were most sensitive to the compliance rates
of the drugs. CONCLUSION: In patients with moderate COPD,
tiotropium was more cost-effective than salmeterol and no treat-
ment strategy. The study helps demonstrate the cost-effectiveness
of new treatment interventions in COPD, which would assist
private payers in evaluating the role of costly, yet effective 
therapies.
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OBJECTIVES: Limited information is available about the rela-
tive beneﬁts of various COPD medication treatments on the out-
comes and treatment costs in a Medicaid population. The
objective was to compare the effects of initial medication regi-
mens on COPD-related and all-cause events (hospitalizations
and/or emergency department visits) and COPD-related and all-
cause costs for patients with COPD. METHODS: A historical
cohort of Texas Medicaid patients aged 40 to 65 years, with
COPD-related medical costs (ICD-9-CM = 491, 492, 496), 24
months of continuous enrollment (12 months pre and post), and
at least one prescription claim (index) for ipratropium (IPR),
inhaled corticosteroids (ICS), salmeterol (SAL) or ﬂuticasone
propionate/salmeterol (FSC) between September 1, 2000, and
December 31, 2003 were assessed. For analysis of events, Cox-
proportional hazards regression analyses were conducted con-
trolling for baseline factors and pre-index events. For analyses
of costs, a two-part model with logistic regression and general-
ized linear model (GLM) were used to adjust for baseline char-
acteristics and pre-index utilization and costs. RESULTS: A total
of 6793 patients were identiﬁed; IPR (n = 4213), ICS (n = 968),
SAL (n = 401) and FSC (n = 1211). EVENTS—Compared with
IPR, only FSC was associated with a signiﬁcantly lower risk of
any COPD-related event (HR 0.733 [95%CI 0.650–0.826]), 
and any all-cause events (HR 0.906 [95%CI 0.844–0.972]).
COSTS—Compared to IPR, total COPD-related costs were
similar in FSC and ICS, and reduced by $108 (p < 0.05) in the
SAL cohort. However, for total all-cause costs, signiﬁcant reduc-
tions were observed for FSC ($792, P < 0.05) and SAL ($1226,
p < 0.05) but not the ICS cohort. CONCLUSION: Compared to
the IPR cohort, the FSC cohort was 27% less likely to have a
COPD-related event, 10% less likely to have any all-cause event,
had similar total COPD-related costs, and had reduced all-cause
treatment costs in COPD patients, indicating that FSC is a cost-
effective initial maintenance therapy compared to IPR.
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ASSESSING TREATMENT EFFECTS OF INHALED
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OBJECTIVES: A longitudinal analysis of managed care claims
data was conducted to estimate the treatment effects of inhaled
corticosteroids (ICS) on medical costs. METHODS: Patients
with Chronic Obstructive Pulmonary Disease (COPD) (ICD-9-
CM: 491, 492 or 496), ages 40 years or older, who had 15
months continuous eligibility, and received both ICS and regular
inhaled bronchodilators (i.e., anticholinergics or long-acting
beta2-agonists) were selected from the claims database. Individ-
ual-level data on exposure status and costs were summarized for
monthly intervals from up to one-year before the initiation of
bronchodilators (“index date”) through a two-year follow-up
period. A ﬁxed-effects approach that accounted for potential
omitted variable biases was used to estimate incremental effects
of initiating ICS on medical costs. Interaction teams were
included to evaluate the timing of ICS treatment as well as
impact of patient age. RESULTS: A total of 10,271 COPD
patients were used in the analysis. After adjusting for time-
variant factors including use of rescue medications and having
conditions of asthma or congestive heart failure, ICS treatment
was associated with monthly cost reduction of $43 in COPD-
related medical services and $55 in all-cause medical services.
Moreover, a one-month delay of ICS initiation was associated
with an additional $2 to $3 per month in medical costs. The
largest cost reduction was observed among older COPD patients.
CONCLUSION: The ﬁndings support evidence that initiation of
ICS treatment earlier than the current guideline recommended
strategy would be beneﬁcial to prevent exacerbation risks and to
reduce overall medical costs from managed care perspective.
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OBJECTIVES: To evaluate the economic value of a new taste-
masked oral clarithromycin preparation (clarithromycin
SipTechnology) by estimating the amount of cost savings due to
its improved compliance compared to clarithromycin suspension
in children with respiratory tract infections (RTI) in Germany.
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METHODS: Treatment failure (TF) in children suffering 
from RTI was derived from the German IMS Disease 
Analyzer–mediplus database totalling 20% of all treatments 
with clarithromycin suspension. TF is due to non-sensitivity 
to clarithromycin or incomplete intake of medication (non-
compliance). The TF rate due to non-compliance on the clar-
ithromycin suspension (13.5%) was calculated from the overall
TF rate (20%) minus the average TF rate due to non-sensitivity
(6.5%). The TF rate due to non-compliance on clarithromycin
SipTechnology was 1.75% as estimated from clinical trial.
Resource utilisation data for treatment of RTI and TF were
obtained from a Delphi panel of paediatricians. The analysis was
conducted from the perspective of the German Statutory Health
Insurance (SHI), including direct costs for physician visits, 
laboratory values, drugs and hospitalizations. Cost data were
derived from published sources for the year 2006. One-way sen-
sitivity analyses were performed. RESULTS: The average costs
of TF totalled €118.05 per case. With an RTI incidence of 
about 426,000 cases among German children aged 2–12 years
and a reduction of TF from 20% to 8.25% (remaining TF 
due to non-sensitivity plus non-compliance on clarithromycin 
SipTechnology) for clarithromycin SipTechnology compared to
clarithromycin suspension, the annual cost-savings for the SHI
amount to about €5.9 million. Sensitivity analyses conﬁrm the
robustness of the results. CONCLUSIONS: Due to its improved
compliance and consequently decreased TF rates, the treatment
with clarithromycin SipTechnology is cost-saving for the German
health care system compared to clarithromycin suspension.
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):
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OBJECTIVES: To examine use and cost of inpatient care by
severity of COPD during one year. METHODS: Using
2004–2005 Massachusetts hospital discharge data, a cohort of
patients with COPD (ICD-9 principal diagnosis codes: 491.2X,
492.X, 493.2, 496) assigned to v15APR-DRG 140 (COPD) was
identiﬁed. A COPD inpatient stay proﬁle was established start-
ing with the ﬁrst hospitalization (index stay) at any Massachu-
setts hospital in 2004 and included all subsequent inpatient stays
for COPD within twelve months. Cases were examined by APR-
DRG severity (mild, moderate, major, extreme). Charges (accom-
modations, ancillary services) adjusted by a 0.652 cost-to-charge
ratio, medical inﬂation and geographic factors are reported as
2006 US$ costs. RESULTS: Of the 11,279 patients 60% were
female, mean age was 69 years. More than half (54%) were clas-
siﬁed as moderate severity; 22% as major, 21% as minor and
4% as extreme. For all COPD cases, the mean LOS was 4.7 days
with a mean cost of $6671 per hospital stay. On average, LOS
and cost increased by severity level from 3.5 days at $4745 for
minor cases to 9 days at $15,997 for extreme cases. The inpa-
tient case fatality rate (CFR) during the index stay ranged from
<1% (minor severity) to 18% (extreme severity). During the sub-
sequent year, 5044 (46% of index survivors) had a COPD-
related readmission. The readmission rate was 39% for minor
cases (mean: 2.2; range: 1–15), 39% for moderate cases (mean:
2.1; range: 1–18), 38% for major cases (mean: 2.1; range: 1–12)
and 20% for extreme cases (mean 2.3; range: 1–10). CON-
CLUSION: Almost half of patients receiving inpatient manage-
ment for COPD will require multiple hospital admissions within
a one year period. Severity of illness impacts duration and cost
of hospital stay, inpatient CFR and readmission rate.
RESPIRATORY DISEASES—Health Care Use & 
Policy Studies
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PERCEPTIONS ABOUT BEHIND-THE-COUNTER AVAILABILITY
OF PSEUDOEPHEDRINE
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OBJECTIVES: Recent federal legislations has mandated phar-
macies to move pseudoephedrine (PSE) products from over-the-
counter to behind-the-counter. We undertook a qualitative study
that explored the public’s perceptions about this new policy.
METHODS: Ninety participants comprising of physicians,
patients, and pharmacists responded to questions about per-
ceived advantages and disadvantages of this policy, its inﬂuence
on the treatment for a common cold, barriers to implementation,
and personal impacts. Qualitative content analysis was per-
formed through the immersion and crystallization process to
identify emerging themes and salient topics. RESULTS: Advan-
tages included more opportunities for pharmacist counseling,
decreased access to pseudoephedrine by minors, less likelihood
for misuse to occur, and less shoplifting. Disadvantages included
rising prices for other cold remedies, less consumer autonomy,
and more pharmacy workload. Implementation barriers involved
lack of consolidated purchase data between various pharmacies
as well as discrepancies between store versus pharmacy hours of
operation. Impact on treatment of colds consisted of substitution
with other over-the-counter remedies and frequent clinic visits
for prescription drugs. CONCLUSION: This exploratory study
suggested actions that might improve the desired effect of the
pseudoephedrine legislation: 1) establishing a universal system 
of linking purchase data among various pharmacies; 2) reducing
the discrepancy between pharmacies’ and stores’ hours of oper-
ation; 3) providing additional support to help the pharmacy 
staff adapt to their new regulatory roles; 4) enhancing 
public awareness about the policy; and 5) studying the economic
effects of this policy on the costs of cold remedies and health
care expenditures.
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OBJECTIVES: The burden of chronic obstructive pulmonary
disease (COPD) and asthma could be reduced through appro-
priate medication therapy management. This study examines 
the relative propensity of Maryland Medicaid managed care
organization (MMMCO) patients with COPD and asthma or
either alone, to be prescribed ﬂuticasone/salmeterol combination
(FSC). METHODS: All medical and prescription claims for
MMMCO enrollees with a diagnosis of COPD (ICD-9 codes
491, 492, 496) and/or asthma (ICD-9 codes 493) in the primary,
or secondary diagnosis ﬁeld, were retrieved. Study patients were
40 and older, claiming at least one FSC or other COPD drug
with a minimum 30 days supply. The propensity of being pre-
scribed FSC was estimated as a logistic function of patient age,
gender, race, general health (as measured by the Charlson
Comorbidity Index), and diagnosis of COPD and/or asthma.
RESULTS: Out of total 9131 patients, half were African-
American, 70% were female and over half were over 50 years
